Colchicine Treatment for Tracheobronchial Amyloidosis

Tracheobronchial amyloidosis is an infrequent disease characterized by the deposition of proteinaceous material in the tracheobronchial tree. The disease generally has a high morbidity and variable mortality in the years following diagnosis. There is no consensus on the optimal treatment. We report a case of a 63-year-old woman who presented with a diffuse tracheobronchial amyloidosis associated with laryngeal involvement, which required a percutaneous tracheostomy due to high-grade subglottic stenosis, with no evidence of systemic amyloidosis. After treatment exclusively with colReceived: May 16, 2015 Accepted after revision: December 21, 2015 Published online: February 9, 2016 Antoni Rosell, MD, PhD, Respiratory Endoscopy Unit, Pulmonology Department IDIBELL, CIBERes, Universitat de Barcelona Hospital Universitari de Bellvitge, Feixa Llarga s/n ES–08907 L’Hospitalet de Llobregat (Spain) E-Mail arosell @ bellvitgehospital.cat © 2016 S. Karger AG, Basel 0025–7931/16/0913–0251$39.50/0 www.karger.com/res Established Facts • Tracheobronchial amyloidosis is a rare disease that can lead to considerable morbidity and mortality. • There is no randomized trial of treatment directed specifically to this disease.